These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37064825)

  • 1. Preferred product attributes of a multipurpose vaginal ring: Findings from a phase 1 trial.
    Tolley EE; Hanif H; Thurman A; Brache V; Doncel GF
    Front Reprod Health; 2023; 5():1148134. PubMed ID: 37064825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acceptability of a Long-Acting, Multipurpose Vaginal Ring: Findings from a Phase I Trial in the U.S. and Dominican Republic.
    Tolley EE; Zissette S; Taylor J; Hanif H; Ju S; Schwarz J; Thurman A; Tyner D; Brache V; Doncel GF
    J Womens Health (Larchmt); 2022 Sep; 31(9):1343-1352. PubMed ID: 35363574
    [No Abstract]   [Full Text] [Related]  

  • 3. User evaluations offer promise for pod-intravaginal ring as a drug delivery platform: A mixed methods study of acceptability and use experiences.
    Guthrie KM; Rosen RK; Vargas SE; Getz ML; Dawson L; Guillen M; Ramirez JJ; Baum MM; Vincent KL
    PLoS One; 2018; 13(5):e0197269. PubMed ID: 29758049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acceptability of an intravaginal ring for simultaneously preventing HIV infection and pregnancy: Qualitative findings of the Kisumu Combined Ring Study, 2019.
    McLellan-Lemal E; Deaton SR; Betts JE; Ondenge K; Mudhune V; O'Connor SM; Nyagol B; Thurman AR; Doncel GF; Allen SA; Heffron R; Mugo NR;
    Contemp Clin Trials; 2022 Nov; 122():106935. PubMed ID: 36162740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Current status of the female condom in Africa].
    Deniaud F
    Sante; 1997; 7(6):405-15. PubMed ID: 9503499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, placebo controlled phase I trial of the safety, pharmacokinetics, pharmacodynamics and acceptability of a 90 day tenofovir plus levonorgestrel vaginal ring used continuously or cyclically in women: The CONRAD 138 study.
    Thurman AR; Brache V; Cochon L; Ouattara LA; Chandra N; Jacot T; Yousefieh N; Clark MR; Peet M; Hanif H; Schwartz JL; Ju S; Marzinke MA; Erikson DW; Parikh U; Herold BC; Fichorova RN; Tolley E; Doncel GF
    PLoS One; 2022; 17(10):e0275794. PubMed ID: 36215267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Novel Microbicide/Contraceptive Intravaginal Ring Protects Macaque Genital Mucosa against SHIV-RT Infection Ex Vivo.
    Villegas G; Calenda G; Ugaonkar S; Zhang S; Kizima L; Mizenina O; Gettie A; Blanchard J; Cooney ML; Robbiani M; Fernández-Romero JA; Zydowsky TM; Teleshova N
    PLoS One; 2016; 11(7):e0159332. PubMed ID: 27428377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An intravaginal ring that releases three antiviral agents and a contraceptive blocks SHIV-RT infection, reduces HSV-2 shedding, and suppresses hormonal cycling in rhesus macaques.
    Derby N; Aravantinou M; Kenney J; Ugaonkar SR; Wesenberg A; Wilk J; Kizima L; Rodriguez A; Zhang S; Mizenina O; Levendosky K; Cooney ML; Seidor S; Gettie A; Grasperge B; Blanchard J; Piatak M; Lifson JD; Fernández-Romero J; Zydowsky TM; Robbiani M
    Drug Deliv Transl Res; 2017 Dec; 7(6):840-858. PubMed ID: 28600625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acceptability and performance of a nonwoven device for vaginal drug delivery among women and their male partners in KwaZulu-Natal, South Africa.
    Hart CW; Joanis C; Hartmann M; Milford C; Smit J; Beksinska M; Rambally-Greener L; Pienaar J; Mabude Z; Butterworth GAM; Sokal D; Jenkins D
    Eur J Contracept Reprod Health Care; 2019 Oct; 24(5):390-398. PubMed ID: 31517545
    [No Abstract]   [Full Text] [Related]  

  • 10. The Tablets, Ring, Injections as Options (TRIO) study: what young African women chose and used for future HIV and pregnancy prevention.
    van der Straten A; Agot K; Ahmed K; Weinrib R; Browne EN; Manenzhe K; Owino F; Schwartz J; Minnis A;
    J Int AIDS Soc; 2018 Mar; 21(3):e25094. PubMed ID: 29600595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acceptability of a Tenofovir Disoproxil Fumarate Intravaginal Ring for HIV Pre-Exposure Prophylaxis Among Sexually Active Women.
    Dobkin A; McWalters J; Barnett R; Ray LL; Espinoza L; McGinn AP; Atrio JM; Keller MJ
    Sex Transm Dis; 2020 Dec; 47(12):819-824. PubMed ID: 33186337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preferred Product Attributes of Potential Multipurpose Prevention Technologies for Unintended Pregnancy and Sexually Transmitted Infections or HIV Among U.S. Women.
    Hynes JS; Sheth AN; Lathrop E; Sales JM; Haddad LB
    J Womens Health (Larchmt); 2019 May; 28(5):665-672. PubMed ID: 30615569
    [No Abstract]   [Full Text] [Related]  

  • 13. Acceptability of an extended duration vaginal ring for HIV prevention and interest in a multi-purpose ring.
    Stoner MCD; Browne EN; Gundacker HM; Hawley I; Chen BA; Hoesley C; Scheckter R; Piper J; Singh D; Song M; Liu A; van der Straten A
    PLoS One; 2022; 17(2):e0263664. PubMed ID: 35192655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Canadian Contraception Consensus (Part 2 of 4).
    Black A; Guilbert E; ; Costescu D; Dunn S; Fisher W; Kives S; Mirosh M; Norman WV; Pymar H; Reid R; Roy G; Varto H; Waddington A; Wagner MS; Whelan AM; ; Ferguson C; Fortin C; Kielly M; Mansouri S; Todd N
    J Obstet Gynaecol Can; 2015 Nov; 37(11):1033-9. PubMed ID: 26629725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women.
    Thurman AR; Schwartz JL; Brache V; Clark MR; McCormick T; Chandra N; Marzinke MA; Stanczyk FZ; Dezzutti CS; Hillier SL; Herold BC; Fichorova R; Asin SN; Rollenhagen C; Weiner D; Kiser P; Doncel GF
    PLoS One; 2018; 13(6):e0199778. PubMed ID: 29953547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaginal Microbiota and Mucosal Pharmacokinetics of Tenofovir in Healthy Women Using a 90-Day Tenofovir/Levonorgestrel Vaginal Ring.
    Thurman AR; Ravel J; Gajer P; Marzinke MA; Ouattara LA; Jacot T; Peet MM; Clark MR; Doncel GF
    Front Cell Infect Microbiol; 2022; 12():799501. PubMed ID: 35350436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canadian Contraception Consensus (Part 1 of 4).
    Black A; Guilbert E; ; Costescu D; Dunn S; Fisher W; Kives S; Mirosh M; Norman WV; Pymar H; Reid R; Roy G; Varto H; Waddington A; Wagner MS; Whelan AM; ; Ferguson C; Fortin C; Kielly M; Mansouri S; Todd N;
    J Obstet Gynaecol Can; 2015 Oct; 37(10):936-42. PubMed ID: 26606712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The ring plus project: safety and acceptability of vaginal rings that protect women from unintended pregnancy.
    Schurmans C; De Baetselier I; Kestelyn E; Jespers V; Delvaux T; Agaba SK; van Loen H; Menten J; van de Wijgert J; Crucitti T;
    BMC Public Health; 2015 Apr; 15():348. PubMed ID: 25880636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Young Women's Ratings of Three Placebo Multipurpose Prevention Technologies for HIV and Pregnancy Prevention in a Randomized, Cross-Over Study in Kenya and South Africa.
    Minnis AM; Roberts ST; Agot K; Weinrib R; Ahmed K; Manenzhe K; Owino F; van der Straten A;
    AIDS Behav; 2018 Aug; 22(8):2662-2673. PubMed ID: 29560570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.